MDGL
Price
$298.04
Change
+$3.40 (+1.15%)
Updated
May 12, 12:46 PM (EDT)
Capitalization
6.54B
86 days until earnings call
MDXG
Price
$7.13
Change
+$0.08 (+1.13%)
Updated
May 12, 12:45 PM (EDT)
Capitalization
1.04B
85 days until earnings call
Ad is loading...

MDGL vs MDXG

Header iconMDGL vs MDXG Comparison
Open Charts MDGL vs MDXGBanner chart's image
Madrigal Pharmaceuticals
Price$298.04
Change+$3.40 (+1.15%)
Volume$200
Capitalization6.54B
MiMedx Group
Price$7.13
Change+$0.08 (+1.13%)
Volume$2.24K
Capitalization1.04B
MDGL vs MDXG Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. MDXG commentary
May 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and MDXG is a Buy.

Ad is loading...
COMPARISON
Comparison
May 12, 2025
Stock price -- (MDGL: $294.64 vs. MDXG: $7.05)
Brand notoriety: MDGL and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 85% vs. MDXG: 164%
Market capitalization -- MDGL: $6.54B vs. MDXG: $1.04B
MDGL [@Biotechnology] is valued at $6.54B. MDXG’s [@Biotechnology] market capitalization is $1.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 2 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 2 bullish, 7 bearish.
  • MDXG’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MDXG is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -6.61% price change this week, while MDXG (@Biotechnology) price change was +11.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.35%. For the same industry, the average monthly price growth was +12.68%, and the average quarterly price growth was -9.35%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

MDXG is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (-1.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.54B) has a higher market cap than MDXG($1.04B). MDGL YTD gains are higher at: -4.514 vs. MDXG (-26.715). MDXG has higher annual earnings (EBITDA): 62.1M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. MDXG (106M). MDXG has less debt than MDGL: MDXG (18.7M) vs MDGL (120M). MDXG has higher revenues than MDGL: MDXG (352M) vs MDGL (317M).
MDGLMDXGMDGL / MDXG
Capitalization6.54B1.04B628%
EBITDA-376.15M62.1M-606%
Gain YTD-4.514-26.71517%
P/E RatioN/A26.11-
Revenue317M352M90%
Total Cash843M106M795%
Total Debt120M18.7M642%
FUNDAMENTALS RATINGS
MDGL vs MDXG: Fundamental Ratings
MDGL
MDXG
OUTLOOK RATING
1..100
5713
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
3476
SMR RATING
1..100
9441
PRICE GROWTH RATING
1..100
5875
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (66) in the Pharmaceuticals Other industry is in the same range as MDXG (71) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MDXG’s over the last 12 months.

MDGL's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDXG (76) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for MDGL (94) in the Pharmaceuticals Other industry. This means that MDXG’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Price Growth Rating (58) in the Pharmaceuticals Other industry is in the same range as MDXG (75) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that MDXG’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLMDXG
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
68%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 12 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
80%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EWZ27.560.08
+0.29%
iShares MSCI Brazil ETF
WBND19.780.05
+0.25%
Western Asset Total Return ETF
VETZ19.760.01
+0.07%
Academy Veteran Impact ETF
PMF8.24N/A
N/A
PIMCO Municipal Income FUND
PFN7.24N/A
N/A
PIMCO Income Strategy Fund II

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
-4.99%
AXON - MDXG
47%
Loosely correlated
-0.33%
VCYT - MDXG
42%
Loosely correlated
-4.81%
OMER - MDXG
40%
Loosely correlated
-2.06%
ARRY - MDXG
39%
Loosely correlated
+8.18%
RAPT - MDXG
38%
Loosely correlated
-5.81%
More